Emergent Biosolutions
(EBS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 254,700 | 300,400 | 276,600 | 270,500 | 337,900 |
| Cost of Goods | 296,100 | 144,600 | 185,100 | 176,800 | 190,600 |
| Gross Profit | -41,400 | 155,800 | 91,500 | 93,700 | 147,300 |
| Operating Expenses | 162,200 | 116,600 | 135,400 | 336,600 | 440,800 |
| Operating Income | -203,500 | 39,800 | -43,800 | -242,100 | -292,900 |
| Interest Expense | 23,600 | 24,300 | 21,700 | 19,700 | 28,600 |
| Other Income | -42,700 | -3,400 | 11,000 | -4,100 | 71,300 |
| Pre-tax Income | -269,800 | 12,100 | -54,500 | -265,900 | -250,200 |
| Income Tax | 13,300 | 3,100 | -5,000 | -2,500 | 11,200 |
| Net Income Continuous | -283,100 | 9,000 | -49,500 | -263,400 | -261,400 |
| Net Income | $-283,100 | $9,000 | $-49,500 | $-263,400 | $-261,400 |
| EPS Basic Total Ops | -5.38 | 0.17 | -0.90 | -5.08 | -5.16 |
| EPS Basic Continuous Ops | -5.38 | 0.17 | -0.90 | -5.08 | -5.16 |
| EPS Diluted Total Ops | -5.38 | 0.17 | -0.90 | -5.08 | -5.16 |
| EPS Diluted Continuous Ops | -5.38 | 0.17 | -0.90 | -5.08 | -5.16 |
| EPS Diluted Before Non-Recurring Items | -2.32 | 0.59 | -0.77 | N/A | N/A |
| EBITDA(a) | $-170,000 | $74,600 | $-8,500 | $9,800 | $-251,100 |